Stockholm, June 27, 2016 — Nasdaq (Nasdaq: NDAQ) announces that the trading in Medical Prognosis Institute A/S’s shares (short name: MPI) commenced today on Nasdaq First North in Stockholm. Medical Prognosis Institute (“MPI”) belongs to the health care sector and is the 48th company to be admitted to trading on Nasdaq’s Nordic markets* in 2016.
MPI is an international precision medicine company specialized in finding personalized cures for cancer. The company uses its core technology and science platform, DRP(TM), to help identify patients who benefit and do not benefit from a specific cancer treatment. MPI is initially focusing on Breast Cancer, Multiple Myeloma and Prostate Cancer, and has tested its DRP technology in 37 clinical trials in a wide range of cancer indications and drugs. MPI has IP covering more than 80 anti-cancer drugs. MPI was founded in 2004 and is headquartered in Hørsholm, Denmark. For more information, please visit www.medical-prognosis.com.
“MPI has a unique Drug Response Predictor Technology which is used in developing Personalized Medicine for cancer patients to predict whether patients will benefit or not from a certain treatment,” said Peter Buhl Jensen, MD, PhD and CEO of MPI. “The listing on Nasdaq First North Stockholm is a natural step in MPI’s communication and transaction with existing and new shareholders.”
“We welcome MPI to Nasdaq First North, one of Europe’s most liquid growth markets,” said Adam Kostyál, senior vice president and head of European listings at Nasdaq. “We congratulate MPI on its listing, and look forward to supporting the company with the increased investor exposure that comes with a Nasdaq First North listing.”
Medical Prognosis Institute A/S has appointed Sedermera Fondkommission AB as the Certified Adviser.
*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm.
About Nasdaq First North
Nasdaq First North is regulated as a multilateral trading facility, operated by the different exchanges within Nasdaq Nordic (Nasdaq First North Denmark is regulated as an alternative marketplace). It does not have the legal status as an EU-regulated market. Companies at Nasdaq First North are subject to the rules of Nasdaq First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market.
Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of over $9.3 trillion and nearly 17,000 corporate clients. To learn more, visit nasdaq.com/ambition or business.nasdaq.com.
Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker Services are respectively brand names for the regulated markets of Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd., Nasdaq Iceland hf., Nasdaq Riga, AS, Nasdaq Stockholm AB, Nasdaq Tallinn AS, AB Nasdaq Vilnius, Nasdaq Clearing AB and Nasdaq Broker Services AB. Nasdaq Nordic represents the common offering by Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq Vilnius.
Cautionary Note Regarding Forward-Looking Statements
The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These factors include, but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.
|Media Relations Contact|
|+46 73 449 78 07|